MX2021011301A - Terapia combinada especifica contra tumores. - Google Patents
Terapia combinada especifica contra tumores.Info
- Publication number
- MX2021011301A MX2021011301A MX2021011301A MX2021011301A MX2021011301A MX 2021011301 A MX2021011301 A MX 2021011301A MX 2021011301 A MX2021011301 A MX 2021011301A MX 2021011301 A MX2021011301 A MX 2021011301A MX 2021011301 A MX2021011301 A MX 2021011301A
- Authority
- MX
- Mexico
- Prior art keywords
- tumor
- combination therapy
- immunotherapy
- selective combination
- nqo1
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Las terapias descritas en la presente pueden ser selectivamente letales contra una diversidad de diferentes tipos de células cancerosas y afecciones cancerosas en un sujeto. Las terapias combinadas descritas en la presente pueden ser útiles para el manejo, tratamiento, control o tratamiento complementario contra enfermedades, en donde la letalidad selectiva es beneficiosa en la inmunoterapia, particularmente cuando la enfermedad es acompañada de niveles elevados de NQO1. En términos particulares, modalidades en las que una inmunoterapia, tal como un inhibidor de puntos de regulación, se combina con un fármaco bioactivable NQO1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962819870P | 2019-03-18 | 2019-03-18 | |
PCT/US2020/023250 WO2020190990A1 (en) | 2019-03-18 | 2020-03-18 | Tumor-selective combination therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021011301A true MX2021011301A (es) | 2022-01-19 |
Family
ID=72519160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021011301A MX2021011301A (es) | 2019-03-18 | 2020-03-18 | Terapia combinada especifica contra tumores. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220160703A1 (es) |
EP (1) | EP3942061A4 (es) |
JP (1) | JP2022525476A (es) |
KR (1) | KR20220004025A (es) |
CN (1) | CN113905763A (es) |
AU (1) | AU2020240035A1 (es) |
BR (1) | BR112021018545A2 (es) |
CA (1) | CA3130513A1 (es) |
MX (1) | MX2021011301A (es) |
WO (1) | WO2020190990A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230128175A (ko) * | 2022-02-25 | 2023-09-04 | 주식회사 온코크로스 | 루복시스타우린을 포함하는 항암용 조성물 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE037382T2 (hu) * | 2010-09-22 | 2018-08-28 | Univ Texas | Eljárás rák kezelésére targeting NQOl alkalmazásával |
CA2909091C (en) * | 2013-04-09 | 2021-11-02 | The Board Of Trustees Of The University Of Illinois | Tumor-selective combination therapy |
EP3334465A1 (en) * | 2015-08-12 | 2018-06-20 | Bayer Pharma Aktiengesellschaft | Pharmaceutical combination for the treatment of cancer |
SG11201808306PA (en) * | 2016-03-24 | 2018-10-30 | Tragara Pharmaceuticals Inc | Treatment of cancer with tg02 |
KR20240006698A (ko) * | 2017-07-21 | 2024-01-15 | 제넨테크, 인크. | 암에 대한 치료 및 진단 방법 |
-
2020
- 2020-03-18 MX MX2021011301A patent/MX2021011301A/es unknown
- 2020-03-18 US US17/440,787 patent/US20220160703A1/en active Pending
- 2020-03-18 CA CA3130513A patent/CA3130513A1/en active Pending
- 2020-03-18 JP JP2021556462A patent/JP2022525476A/ja active Pending
- 2020-03-18 KR KR1020217033464A patent/KR20220004025A/ko unknown
- 2020-03-18 AU AU2020240035A patent/AU2020240035A1/en active Pending
- 2020-03-18 WO PCT/US2020/023250 patent/WO2020190990A1/en unknown
- 2020-03-18 EP EP20773832.9A patent/EP3942061A4/en active Pending
- 2020-03-18 BR BR112021018545A patent/BR112021018545A2/pt unknown
- 2020-03-18 CN CN202080037114.7A patent/CN113905763A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3942061A1 (en) | 2022-01-26 |
EP3942061A4 (en) | 2022-12-14 |
BR112021018545A2 (pt) | 2021-12-14 |
CN113905763A (zh) | 2022-01-07 |
WO2020190990A1 (en) | 2020-09-24 |
US20220160703A1 (en) | 2022-05-26 |
AU2020240035A1 (en) | 2021-10-07 |
KR20220004025A (ko) | 2022-01-11 |
CA3130513A1 (en) | 2020-09-24 |
JP2022525476A (ja) | 2022-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020008581A (es) | Oligonucleotidos antisentido de la proteina cinasa del tipo ii delta dependiente del calcio/calmodulina (camk2d) y sus usos. | |
WO2018049152A8 (en) | Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
MX2021000828A (es) | Uso de farmacos bioactivables por nqo1 para mejorar la actividad inhibidora de parp1. | |
MX2023001527A (es) | Compuestos con actividad inductora de ferroptosis y metodos de uso de estos. | |
EA201991622A1 (ru) | Комплексная терапия для лечения рака | |
EP4253412A3 (en) | Inhibition of cytokine-induced sh2 protein in nk cells | |
MX2020009773A (es) | Terapia de combinacion. | |
GB2467670A (en) | Chemical entities and therapeutic uses thereof | |
MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
CY1123501T1 (el) | Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος | |
WO2016090024A3 (en) | Combination therapy for treatment of cancer | |
MX2021010173A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso. | |
MX2021013608A (es) | Composiciones y métodos de fabricacion de celulas t. | |
MX2023001450A (es) | Composiciones y metodos para la inhibicion de la expresion de plp1. | |
MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
MX2020001727A (es) | Terapia de combinacion. | |
MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
AU2018271862A1 (en) | Combination therapy | |
EP4063522A4 (en) | COMPOSITION FOR PREDICTING RESPONSE TO STANDARD PREOPERATIVE CHEMORADIOTHERAPY AND POST-TREATMENT PROGNOSIS, AND METHOD AND COMPOSITION FOR PREDICTING PATIENTS LIKELY TO HAVE VERY UNSATISFACTORY PROGNOSES AFTER STANDARD THERAPY | |
MX2021011301A (es) | Terapia combinada especifica contra tumores. | |
BR112023021913A2 (pt) | Tratamento de câncer com inibidor de raf | |
BR112018067967A2 (pt) | tratamento de pacientes com hipercolesterolemia familiar homozigótica por meio de terapia hipolipemiante | |
MX2021014008A (es) | Moléculas pequeñas para tratar el cáncer, inhibir la actividad de quimiocinas y/o inducir la muerte celular. | |
MX2021010603A (es) | Inhibidores de caspasa y metodos de uso de los mismos. |